NewEdge Advisors’s Intellia Therapeutics NTLA Stock Holding History

NewEdge Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$17.9K	Sell	1,400 -200	-13%	-$2.55K	﹤0.01%	3226
2025 Q4	$14.4K	Sell	1,600 -685	-30%	-$9.43K	﹤0.01%	3355
2025 Q3	$39.5K	Hold	2,285	–	–	﹤0.01%	2899
2025 Q2	$21.4K	Buy	2,285 +800	+54%	+$6.57K	﹤0.01%	2935
2025 Q1	$10.6K	Buy	+1,485	New	+$15K	﹤0.01%	3082
2024 Q4	–	Sell	-300	Closed	-$6.17K	–	3981
2024 Q3	$6.17K	Buy	+300	New	+$6.92K	﹤0.01%	3090
2024 Q2	–	Sell	-40	Closed	-$1.1K	–	3943
2024 Q1	$1.1K	Buy	+40	New	+$1.11K	﹤0.01%	3480
2023 Q4	–	Sell	-3	Closed	-$95	–	3838
2023 Q3	$95	Sell	3 -333	-99%	-$12.9K	﹤0.01%	3368
2023 Q2	$13.7K	Sell	336 -183	-35%	-$7.42K	﹤0.01%	2503
2023 Q1	$19.3K	Sell	519 -725	-58%	-$28.4K	﹤0.01%	2354
2022 Q4	$28.7K	Buy	+1,244	New	+$59.1K	﹤0.01%	1984

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

NewEdge Advisors's NTLA Position: Q1 2026 in Review

NewEdge Advisors reduced its Intellia Therapeutics (NTLA) stake by 13% in Q1 2026, selling an estimated $2.55K and leaving 1,400 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3226.

NewEdge Advisors first reported a position in NTLA in Q4 2022 and has held it in 11 quarters since. The position peaked at $39.5K in Q3 2025. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

NewEdge Advisors held 1,400 shares of Intellia Therapeutics worth $17.9K as of Q1 2026.
NewEdge Advisors sold 200 Intellia Therapeutics shares in Q1 2026, an estimated $2.55K.
Intellia Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3226 holding.
NewEdge Advisors first reported a position in Intellia Therapeutics in Q4 2022 and has held it in 11 quarters since.
NewEdge Advisors's Intellia Therapeutics position peaked at $39.5K in Q3 2025.
302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.